NCT07067346View on ClinicalTrials.gov

Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Neuroblastoma

Interventions

DRUG

IR-101

IR-101 Dose Escalation

Trial Locations (2)

Unknown

RECRUITING

West China Hospital, Chengdu

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors

lead

Sichuan University

OTHER